Memantine Orion (Memantine Hydrochloride)

Memantine works as a non‑competitive antagonist of the NMDA receptor. By blocking excessive calcium influx through the receptor’s ion channel, it limits glutamate‑induced excitotoxicity while allowing normal synaptic activity, thereby protecting neurons in Alzheimer’s disease.

The dosing regimen for Memantine Orion is determined by the prescribing clinician based on the patient’s condition, renal function, and tolerability. The prescriber will set the appropriate dose and titration schedule.

Safety data for memantine in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To place an order, submit an enquiry on the product page at gnhindia.com specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Memantine belongs to the NMDA receptor antagonist class, whereas other approved agents such as donepezil, rivastigmine and galantamine are acetylcholinesterase inhibitors. Memantine is typically used in moderate to severe stages and may be combined with an acetylcholinesterase inhibitor for additive benefit.

Memantine Orion should be stored at ambient temperature, below 25 °C. Keep the product in its original packaging, protect it from moisture and direct sunlight, and ensure the container is tightly closed to maintain stability.

Memantine Orion is taken orally, usually as a tablet or capsule, with or without food. The exact administration schedule is set by the prescriber and should be followed exactly as instructed.

Serious risks include seizures, cardiac arrhythmias, severe hepatic dysfunction, and rare but life‑threatening skin reactions such as Stevens‑Johnson syndrome. Patients should be monitored for any new or worsening symptoms and seek medical attention promptly if serious adverse events occur.

Memantine Orion is contraindicated in patients with known hypersensitivity to memantine or any of its excipients. Caution is advised in individuals with severe renal impairment, uncontrolled hypertension, or a history of seizures, and it should be avoided in combination with other NMDA antagonists.